Protocol Ledger

NCT06665100 · Phase II · RECRUITING

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Interventional Phase II clinical trial protocol NCT06665100 sponsored by Pulmotect in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-27 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06665100
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06665100
Protocol FieldVerified Registry Value
NCT IdentifierNCT06665100
Consolidated Lead SponsorPulmotect
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2025-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI